- Home
- AUPH vs IMKTA Comparison
AUPH vs IMKTA Comparison
Compare AUPH & IMKTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- IMKTA
- Stock Information
- Founded
- AUPH 1993
- IMKTA 1963
- Country
- AUPH Canada
- IMKTA United States
- Employees
- AUPH N/A
- IMKTA N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- IMKTA Food Chains
- Sector
- AUPH Health Care
- IMKTA Consumer Staples
- Exchange
- AUPH Nasdaq
- IMKTA Nasdaq
- Market Cap
- AUPH 1.6B
- IMKTA 1.3B
- IPO Year
- AUPH 1999
- IMKTA N/A
- Fundamental
- Price
- AUPH $12.54
- IMKTA $72.48
- Analyst Decision
- AUPH Strong Buy
- IMKTA
- Analyst Count
- AUPH 2
- IMKTA 0
- Target Price
- AUPH $13.00
- IMKTA N/A
- AVG Volume (30 Days)
- AUPH 1.2M
- IMKTA 82.8K
- Earning Date
- AUPH 11-10-2025
- IMKTA 08-07-2025
- Dividend Yield
- AUPH N/A
- IMKTA 0.92%
- EPS Growth
- AUPH N/A
- IMKTA N/A
- EPS
- AUPH 0.42
- IMKTA 2.97
- Revenue
- AUPH $260,111,000.00
- IMKTA $5,363,138,171.00
- Revenue This Year
- AUPH $17.33
- IMKTA N/A
- Revenue Next Year
- AUPH $14.31
- IMKTA N/A
- P/E Ratio
- AUPH $30.05
- IMKTA $24.19
- Revenue Growth
- AUPH 25.59
- IMKTA N/A
- 52 Week Low
- AUPH $6.55
- IMKTA $58.92
- 52 Week High
- AUPH $13.54
- IMKTA $75.63
- Technical
- Relative Strength Index (RSI)
- AUPH 60.86
- IMKTA 55.29
- Support Level
- AUPH $11.48
- IMKTA $71.50
- Resistance Level
- AUPH $12.70
- IMKTA $75.22
- Average True Range (ATR)
- AUPH 0.34
- IMKTA 1.50
- MACD
- AUPH 0.13
- IMKTA -0.28
- Stochastic Oscillator
- AUPH 89.64
- IMKTA 50.27
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About IMKTA Ingles Markets Incorporated
Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.